

IMMUNOCORE

targeting T cell receptors

PRESS RELEASE – IMMUNOCORE LIMITED

Immunocore Ranked in the Sunday Times Hiscox Tech Track 100

(Oxford, UK, 12 September 2016) Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, viral infections and autoimmune disease, today notes that it has been ranked fourth overall in the 16th annual Sunday Times Hiscox Tech Track 100. Immunocore appears in the league table for the second time, rising up the rank from ninth place in 2015.

The Sunday Times Hiscox Tech Track 100 league table ranks the top 100 private British technology, media and telecoms (TMT) companies with the fastest-growing revenues over the past three years.

The Tech Track 100 is compiled by Fast Track in association with The Sunday Times on an annual basis and adopts the London Stock Exchange's techMARK definition of a technology company as one 'that shows a commitment to innovation, research and product development, and operates in sectors including software, internet, telecoms and biotech'.

Eva-Lotta Allan, Chief Business Officer at Immunocore, commented: "We are delighted that our continued growth and performance has been recognised through the inclusion in the prestigious Tech Track 100 for the second year running. This is an exciting time for Immunocore, and we are thankful for this continued support as we develop our portfolio of immuno-oncology and infectious disease assets and continue our mission to become a world leader in biotechnology."

– ENDS –

For more information, please contact:

Immunocore

Eliot Forster, Chief Executive Officer

T: +44 (0)1235 438600

E: info@immunocore.com

Consilium Strategic Communications

Mary-Jane Elliott/Jessica Hodgson/Chris Welsh/Laura Thornton

T: +44 (0)203 709 5700

E: Immunocore@consilium-comms.com

IMMUNOCORE

targeting T cell receptors

Notes for editors

About Immunocore

Immunocore is one of the world's leading biotechnology companies, with a highly innovative immuno-oncology platform technology called ImmTACs. ImmTACs are a novel class of biologic drugs based on the Company's proprietary T cell receptor (TCR) technology which have the potential to treat diseases with high unmet medical need including cancer, infectious diseases and autoimmune diseases. Immunocore, based on decades of world-leading scientific innovation in the discovery of HLA targets and T cell receptor technology, has a pipeline of wholly-owned and partnered ImmTAC programmes with robust clinical data, validated by collaborations with world-leading pharmaceutical companies. Immunocore is developing programmes with its TCR-based platform as a potential therapy for HIV and other infectious diseases. Immunocore aims to leverage the utility of its platform across a wide range of indications to become a Premier Biotech company and world-leader in its field.

Immunocore's world-leading science and strong IP position has attracted major pharmaceutical companies including Genentech, GlaxoSmithKline, MedImmune, the biologics division of AstraZeneca, via discovery collaborations, as well as a co-discovery and co-development partnership with Lilly. The Company has also entered into combination trials with its lead programme, IMCgp100 in metastatic melanoma, with MedImmune and Lilly. Founded in 2008 originally out of Oxford University and headquartered outside Oxford with US offices outside Philadelphia, Immunocore now has more than 280 staff. Immunocore's current investors are well-renowned, leading international institutions including Woodford Investment Management, Malin Corporation, Eli Lilly and Company, RTW Investments, Fidelity Management & Research Company as well as other private shareholders. For more information, please visit www.immunocore.com

Sunday Times Hiscox Tech Track 100

The Sunday Times Hiscox Tech Track 100 adopts the London Stock Exchange's (LSE) techMARK definition of a technology company as one 'that shows a commitment to innovation, research and product development, and operates in sectors including software, internet, telecoms and biotech'. Companies had to be registered in the UK and be independent, unquoted and ultimate holding companies. Companies were ranked according to the compound annual growth rate in sales over three years, based on their latest available figures (either 2012 to 2015, or 2013 to 2016). The research therefore carries the caveat that their performance may have changed since. Annualised sales had to exceed £250,000 in the base year (2012 or 2013) and £5m in the latest year (2015 or

IMMUNOCORE

targeting T cell receptors

2016). Companies also had to increase sales in the latest year, but did not need to be in profit. The majority of companies were interviewed by telephone or visited by the Fast Track research team.